Development

Cogent advances bezuclastinib toward approval across three mastocytosis indications simultaneously

Cogent Biosciences (Nasdaq: COGT) has submitted its third New Drug Application to the US FDA in six months, filing for bezuclastinib in advanced systemic...

Cogent advances bezuclastinib toward approval across three mastocytosis indications simultaneously

Cogent Biosciences has submitted an NDA for bezuclastinib in advanced systemic mastocytosis (AdvSM), completing a trio of FDA filings for the KIT D816V inhibitor across three indications within six months. Supported by pivotal APEX trial data, the filing positions bezuclastinib as a potential challenger to the current treatment standard in AdvSM while giving Cogent three simultaneous FDA reviews for the same asset across advanced systemic mastocytosis, non-advanced systemic mastocytosis (NonAdvSM), and gastrointestinal stromal tumors (GIST).

AdvSM comprises aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia, all of which carry substantially poorer prognoses than non-advanced disease. The NDA is supported by data from the pivotal APEX trial, which enrolled 81 patients treated with bezuclastinib 150 mg.

Among 68 evaluable patients assessed using modified International Working Group–Myeloproliferative Research and Treatment–European Competence Network on Mastocytosis (mIWG-MRT-ECNM) criteria, bezuclastinib achieved a 65% overall response rate, with 57% of patients attaining complete remission, complete remission with partial hematologic recovery, or partial remission. Using pure pathological response criteria across all 81 treated patients, overall response reached 81%.

The responses were accompanied by encouraging durability. Twelve-month progression-free survival was 79% and overall survival was 87%, with median values for both endpoints not yet reached. Biomarker improvements were similarly pronounced, with approximately 90% of patients achieving at least a 50% reduction in serum tryptase, bone marrow mast cell burden, or KIT D816V variant allele frequency. Around one-third of patients achieved undetectable KIT D816V, suggesting deep molecular responses.

Safety findings were consistent with previous experience. The most common treatment-related adverse events were hair color changes, neutropenia, dysgeusia, thrombocytopenia, and transient ALT/AST elevations. Liver enzyme elevations were generally low grade, asymptomatic, and reversible, with treatment discontinuations due to adverse events reported infrequently.

The AllSci BriefSystematic R&D and deal news. Daily.

The competitive landscape in AdvSM is currently led by Blueprint Medicines' Ayvakit (avapritinib), which demonstrated substantial efficacy but carries labeled risks of intracranial hemorrhage and cognitive adverse effects associated with central nervous system penetration. Novartis' Rydapt (midostaurin), approved in 2017, remains an option but is a broader multikinase inhibitor with a less selective safety profile. Bezuclastinib was designed with minimal CNS penetration, a feature that could provide meaningful differentiation if its efficacy and tolerability are confirmed during regulatory review and longer-term follow-up. Cross-trial comparisons remain inherently limited by differences in study design and patient populations.

The AdvSM submission follows two earlier FDA filings for bezuclastinib. The company's NDA for NonAdvSM was accepted in March 2026 with a PDUFA date of December 30, 2026, while its GIST application received Priority Review in May 2026 with a November 30, 2026 target action date. Cogent expects its first bezuclastinib approvals in Q4 2026 through those two applications. The AdvSM filing, based on the APEX data presented at the 2026 European Hematology Association Congress, is awaiting FDA acceptance and a PDUFA date.

With three regulatory reviews now underway for the same molecule, Cogent is entering a pivotal period in its development strategy. If approved, bezuclastinib could expand beyond its initial indications to become a differentiated KIT D816V inhibitor across multiple mast cell disorders and GIST, with the AdvSM application representing the company's opportunity to compete directly in the highest-risk form of systemic mastocytosis.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/


Spot something wrong? Report an issue with this article